What is Tempus AI and Why It's Important
The world of medicine often feels deeply personal, yet its systems can be frustratingly opaque and inefficient. This became starkly clear to Eric Lefkofsky when his wife faced breast cancer, prompting him to found Tempus AI in 2015. He envisioned harnessing technology for more precise, patient-centric care. Headquartered in Chicago, Illinois, Tempus AI embarked on a mission to empower physicians with data-driven insights, aiming to personalize patient care and accelerate drug development.
Source: The company was founded in 2015 with a vision to harness technology for more precise, patient-centric care, empowering physicians with data-driven insights.
Quick Summary:
- Founded: 2015 by Eric Lefkofsky after his wife’s cancer diagnosis.
- Mission: To provide data-driven insights to physicians for personalized patient care and accelerated drug development.
- Core Technology: Utilizes AI and one of the world’s largest libraries of multimodal clinical and molecular data (over 40 million de-identified datasets, 350+ petabytes).
- Key Areas: Genomics and precision medicine, primarily for cancer, but also cardiology, radiology, and pharmacogenomics.
- Business Model: Genomics (high-throughput sequencing), Data & Services (licensing insights to pharma), and Applications (AI tools for clinical workflows).
- Partnerships: Over 200 biopharma companies, including 95% of top 20 pharma oncology firms; connected with over 50% of US oncologists and 65% of academic medical centers.
- Products: Tempus ONE (AI smart speaker), Olivia (AI health concierge app), AI diagnostics (e.g., Tumor Origin Test, ECG-AF algorithm), Tempus Pixel (AI for radiology).
- Recent Developments: Acquired Paige (digital pathology) and Ambry Genetics (gene testing); joint venture SB Tempus in Japan; IPO in June 2024.
- Financials: Strong revenue growth (e.g., $314.6M Q2 2025, nearly 90% YOY increase); aiming for adjusted EBITDA profitability in 2025.
Tempus AI: Powering Precision Medicine with Data
Tempus AI positions itself at the forefront of precision medicine, utilizing artificial intelligence to revolutionize healthcare. The company operates on a foundation built from one of the world's largest libraries of multimodal clinical and molecular data, encompassing over 40 million de-identified research datasets and exceeding 350 petabytes of data. This vast repository fuels its core focus on genomics and precision medicine, primarily for cancer patients, though its applications extend to cardiology, radiology, and pharmacogenomics for depression.
The company's business model is structured around three key pillars:
- Genomics: Specializes in high-throughput sequencing of tumor DNA and RNA to identify genetic mutations, enabling personalized cancer treatments.
- Data & Services: Licenses insights derived from its extensive de-identified patient dataset to pharmaceutical companies for drug development.
- Applications: Integrates AI-powered tools directly into clinical workflows, enhancing decision-making for physicians.
Tempus AI has forged significant partnerships across the healthcare landscape. It collaborates with over 200 biopharma companies, including more than 95% of the top 20 pharma oncology firms. Its reach extends deep into the medical community, with over 50% of oncologists in the US connected through sequencing, clinical trials, and research partnerships, and approximately 65% of all academic medical centers in the US linked to the company. This extensive network has allowed Tempus AI to identify over 40,000 patients for potential enrollment in clinical trials.
Technological Innovations and Product Offerings
Tempus AI's suite of products is designed to translate complex data into actionable insights for medical professionals.
Source: frolicstudio.com
Tempus ONE, an AI-powered smart speaker, provides real-time answers to physicians queries and expands the Tempus AI data pool.
Tempus ONE, an AI-powered smart speaker, provides real-time answers to physicians' queries, simultaneously expanding Tempus AI's data pool by capturing conversational data. Olivia, an AI-driven health concierge app, integrates with fitness trackers and health records to offer personalized health management tips and lifestyle advice. The company also develops AI diagnostics, including algorithms like the Tumor Origin Test and the ECG-AF algorithm, which enhance diagnostic precision for conditions such as cancer and atrial fibrillation.
A notable achievement in its diagnostic offerings is the U.S. FDA 510(k) clearance for its Tempus ECG-Low EF (Ejection Fraction) Software. This AI-powered tool identifies patients with low left ventricular ejection fraction (LVEF). In a move highlighting integration into existing clinical infrastructure, Northwestern Medicine became the first health system to integrate David, Tempus AI's generative AI clinical co-pilot, into its electronic health record (EHR) system.
Strategic Expansions and Acquisitions
Further expanding its capabilities, Tempus AI acquired Paige, an AI digital pathology company, to broaden its dataset and strengthen its presence in digital pathology. The company also entered a joint venture with SoftBank in June 2024, establishing SB Tempus in Japan. This collaboration aims to develop personalized treatment recommendations by analyzing medical data with AI.
Source: prnewswire.com
In November 2024, Tempus AI agreed to acquire Ambry Genetics, a California-based gene testing company, to bolster its gene testing business.
More recently, in November 2024, Tempus AI agreed to acquire the California-based gene testing company Ambry Genetics for $600 million in a cash-and-stock deal, which was finalized on February 3, 2025, to bolster its gene testing business.
Financial Landscape and Future Prospects
Tempus AI entered the public market in June 2024, raising $410.7 million at a share price of $37, which valued the company at $6.1 billion. By October 2024, the stock was trading at $46. The company announced on February 24, 2026, that it will release its fourth-quarter and full-year 2025 financial results.
Revenue Growth and Profitability
The company’s financial performance has shown significant growth. Tempus AI reported revenue of $314.6 million in the second quarter of 2025, marking nearly a 90% increase year-over-year. Total revenues for 2024 reached $693.4 million, representing a 268.8% increase over four years with a compound annual growth rate (CAGR) of 38.6%. While revenue growth cooled to 30.4% in 2024 from 65.8% in 2023, the company generated $531 million in revenue in 2023 and projected $700 million for 2024 (a 32% increase). Management has set an ambitious revenue target of $1.24 billion for 2025, a 78% jump, partly driven by the Ambry Genetics acquisition.
Despite robust revenue growth, Tempus AI reported operating losses of approximately $284 million for the 12 months ending March 31, 2024. Its net loss for 2024 was $705.8 million, with roughly $500 million attributed to stock-based compensation. However, management anticipates an adjusted EBITDA of approximately $5 million for 2025. The gross profit margin has seen substantial improvement, rising from 15.3% in 2020 to 55% in 2024.
Financial Health Overview
| Metric | 2023 (or prior) | 2024 | 2025 (Projected) |
|---|---|---|---|
| Total Revenue | $531M | $693.4M | $1.24B |
| Revenue Growth | 65.8% | 30.4% | 78% |
| Operating Losses | N/A | ~$284M (12 months ending Mar 31, 2024) | N/A |
| Net Loss | N/A | $705.8M | N/A |
| Adjusted EBITDA | N/A | N/A | ~$5M |
| Gross Profit Margin | 15.3% (2020) | 55% | N/A |
| Cash Position | $165.7M | $340.9M | N/A |
Tempus AI ended 2024 with a cash position of $340.9 million, a significant increase from $165.7 million the previous year. Ares Management provided a $350 million loan and revolving credit facility, due in 2030. The company's receivables stood at $154.8 million at the end of 2024, up from $94.5 million, and marketable securities increased from $31.8 million to $107.3 million year-over-year, partly due to the settlement of receivables in stock. Tempus AI currently employs around 2,300 individuals.
Strategic Growth Areas
Tempus AI plans to broaden its operations into neurology and rare diseases, while also expanding its global footprint into markets across Europe and Asia. The company leverages advanced machine learning techniques, including deep neural networks and natural language processing, to analyze biomedical datasets. Its platform seamlessly integrates with electronic health records (EHRs), laboratory databases, and imaging archives. Tempus AI offers a genome profiling module for analyzing genetic variants linked to specific diseases, and a comprehensive biomarker discovery tool that identifies new indicators for disease susceptibility or treatment response. The platform also provides predictive analytics, simulating potential outcomes under various treatment scenarios, and adheres to HIPAA and GDPR compliance regulations.
Tempus AI's partnerships extend to key areas of innovation, such as the collaboration with AstraZeneca to advance oncology therapeutics. The Tempus TIME Trial Network provides crucial infrastructure to expedite Phase 1 clinical trials. Additionally, Tempus Pixel, an FDA-approved, CE-marked AI-powered solution, delivers advanced analytics and automated reports from radiological images. Tempus AI is also working with eyonis® to integrate its Lung Cancer Screening (LCS) into the Tempus Pixel platform for non-invasive lung nodule characterization.
Source: personalis.com
Tempus AI has secured Medicare coverage for the NeXT Personal® molecular residual disease (MRD) test for monitoring non-small cell lung cancer patients.
The company has secured Medicare coverage for the NeXT Personal® molecular residual disease (MRD) test for monitoring stage I to III non-small cell lung cancer (NSCLC) patients. Over 70% of Tempus AI’s multimodal datasets available for immediate research include RNA data.
Conclusion
Tempus AI's journey from a personal experience with illness to a leader in AI-driven precision medicine underscores a significant shift in healthcare. By building a vast data infrastructure and developing sophisticated AI tools, the company aims to move medicine towards highly personalized treatments and accelerated drug discovery. While grappling with the financial demands of rapid expansion and R&D, its strategic acquisitions, robust partnerships, and growing suite of products position it as a formidable force in transforming how medical decisions are made. The focus on integrating advanced analytics into clinical practice has the potential to fundamentally reshape patient care across numerous disease areas.
Frequently Asked Questions (FAQs)
What is Tempus AI's primary mission?
Tempus AI’s core mission is to empower physicians with data-driven decisions in real-time, aiming to personalize patient care and accelerate drug development by leveraging AI and a vast library of multimodal clinical and molecular data.
How does Tempus AI use artificial intelligence?
Tempus AI uses advanced machine learning techniques, including deep neural networks and natural language processing, to analyze biomedical datasets. This helps in identifying genetic mutations, discovering biomarkers, providing predictive analytics, and enhancing diagnostic precision across various medical fields.
What types of data does Tempus AI collect and utilize?
Tempus AI utilizes one of the world’s largest libraries of multimodal clinical and molecular data, including over 40 million de-identified research datasets and over 350 petabytes of information. This data integrates from electronic health records (EHRs), laboratory databases, and imaging archives.
What are some of Tempus AI's key products?
Key products include Tempus ONE (an AI-powered smart speaker for physicians), Olivia (an AI-driven health concierge app), AI diagnostics like the Tumor Origin Test and ECG-AF algorithm, and Tempus Pixel (an AI-powered solution for radiological image analysis). They also offer genome profiling and biomarker discovery tools.
Has Tempus AI acquired other companies?
Yes, Tempus AI has made significant acquisitions, including Paige, an AI digital pathology company, and Ambry Genetics, a gene testing company. These acquisitions aim to expand its dataset and strengthen its presence in digital pathology and gene testing.